{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:35:24Z","timestamp":1792683324491,"version":"4.5.0"},"reference-count":126,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This systematic review summarises the stability of less commonly prescribed antibiotics in different peritoneal dialysis solutions that could be used for culture-directed therapy of peritonitis, which would be especially useful in regions with a high prevalence of multidrug antibiotic-resistant strains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A literature search of Medline, Scopus, Embase and Google Scholar for articles published from inception to 25 January, 2023 was conducted. Only antibiotic stability studies conducted in vitro and not recently reviewed by So et al\n                      <jats:italic>.<\/jats:italic>\n                      were included. The main outcomes were chemical, physical, antimicrobial and microbial stability.\u00a0This protocol was registered in PROSPERO (registration number CRD42023393366).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We screened 1254 abstracts, and 28 articles were included in the study. In addition to those discussed in a recent systematic review (So et al., Clin Kidney J 15(6):1071\u20131078, 2022), we identified 18 antimicrobial agents. Of these, 9 have intraperitoneal dosing recommendations in the recent International Society for Peritoneal Dialysis (ISPD) peritonitis guidelines, and 7 of the 9 had stability data applicable to clinical practice. They were cefotaxime, ceftriaxone, daptomycin, ofloxacin, and teicoplanin in glucose-based solutions, tobramycin in Extraneal solution only and fosfomycin in Extraneal, Nutrineal, Physioneal 1.36% and 2.27% glucose solutions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Physicochemical stability has not been demonstrated for all antibiotics with intraperitoneal dosing recommendations in the ISPD peritonitis guidelines. Further studies are required to determine the stability of antibiotics, especially in icodextrin-based and low-glucose degradation products, pH-neutral solutions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-023-01716-7","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T05:02:45Z","timestamp":1691384565000},"page":"1841-1859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Culture-directed antibiotics in peritoneal dialysis solutions: a systematic review\u00a0focused on stability and compatibility"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6445-4314","authenticated-orcid":false,"given":"Chau Wei","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Sud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Wanandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siang Fei","family":"Yeoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Van","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Castelino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"issue":"3","key":"1716_CR1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/089686080902900314","volume":"29","author":"A Davenport","year":"2009","unstructured":"Davenport A (2009) Peritonitis remains the major clinical complication of peritoneal dialysis: the London, UK, peritonitis audit 2002\u20132003. Perit Dial Int 29(3):297\u2013302","journal-title":"Perit Dial Int"},{"issue":"3","key":"1716_CR2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/oxfordjournals.ndt.a027318","volume":"11","author":"SJ Davies","year":"1996","unstructured":"Davies SJ, Bryan J, Phillips L, Russell GI (1996) Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transpl 11(3):498\u2013506","journal-title":"Nephrol Dial Transpl"},{"issue":"49","key":"1716_CR3","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005569","volume":"95","author":"Y Tian","year":"2016","unstructured":"Tian Y, Xie X, Xiang S, Yang X, Zhang X, Shou Z et al (2016) Risk factors and outcomes of high peritonitis rate in continuous ambulatory peritoneal dialysis patients: a retrospective study. Medicine (Baltimore) 95(49):e5569","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1716_CR4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/08968608221080586","volume":"42","author":"PK-T Li","year":"2022","unstructured":"Li PK-T, Chow KM, Cho Y, Fan S, Figueiredo AE, Harris T et al (2022) ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 42(2):110\u2013153","journal-title":"Perit Dial Int"},{"issue":"6","key":"1716_CR5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/ckj\/sfac012","volume":"15","author":"SWY So","year":"2022","unstructured":"So SWY, Chen L, Woo AYH, Ng DMH, Wong JKW, Chow KM et al (2022) Stability and compatibility of antibiotics in peritoneal dialysis solutions. Clin Kidney J 15(6):1071\u20131078","journal-title":"Clin Kidney J"},{"key":"1716_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfac131","author":"CW Ling","year":"2022","unstructured":"Ling CW, Sud K, Patel RP, Peterson GM, Castelino RL (2022) Stability and compatibility of antibiotics in PD solutions\u2014call for including antibiotics for drug-resistant infections. Clin Kidney J. https:\/\/doi.org\/10.1093\/ckj\/sfac131","journal-title":"Clin Kidney J"},{"issue":"7","key":"1716_CR7","first-page":"1159","volume":"40","author":"LA Trissel","year":"1983","unstructured":"Trissel LA (1983) Avoiding common flaws in stability and compatibility studies of injectable drugs. Am J Hosp Pharm 40(7):1159\u20131160","journal-title":"Am J Hosp Pharm"},{"issue":"2","key":"1716_CR8","first-page":"79","volume":"2","author":"J-D Hecq","year":"2017","unstructured":"Hecq J-D, Bihin B, Jamart J, Galanti L (2017) Criteria for judging the quality of a publication on physicochemical stability of ready to use injectable drugs. Pharm Technol Hosp Pharm 2(2):79\u201384","journal-title":"Pharm Technol Hosp Pharm"},{"issue":"4","key":"1716_CR9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/BF00613528","volume":"31","author":"H Albin","year":"1986","unstructured":"Albin H, Ragnaud JM, Demotes-Mainard F, Vin\u00e7on G, Couzineau M, Wone C (1986) Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis. Eur J Clin Pharmacol 31(4):479\u2013483","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1716_CR10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/clpt.1985.172","volume":"38","author":"HC Albin","year":"1985","unstructured":"Albin HC, Demotes-Mainard FM, Bouchet JL, Vincon GA, Martin-Dupont C (1985) Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis. Clin Pharmacol Ther 38(3):285\u2013289","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1716_CR11","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/089686080802800520","volume":"28","author":"MF Lam","year":"2008","unstructured":"Lam MF, Tang BSF, Tse KC, Chan TM, Lai KN (2008) Ampicillin-sulbactam and amikacin used as second-line antibiotics for patients with culture-negative peritonitis. Perit Dial Int 28(5):540\u2013542","journal-title":"Perit Dial Int"},{"issue":"6","key":"1716_CR12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1159\/000363417","volume":"39","author":"SA Silver","year":"2014","unstructured":"Silver SA, Harel Z, Perl J (2014) Practical considerations when prescribing icodextrin: a narrative review. Am J Nephrol 39(6):515\u2013527","journal-title":"Am J Nephrol"},{"issue":"4","key":"1716_CR13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/ndt\/gfg518","volume":"19","author":"M Fischbach","year":"2004","unstructured":"Fischbach M, Terzic J, Chauv\u00e9 S, Laugel V, Muller A, Haraldsson B (2004) Effect of peritoneal dialysis fluid composition on peritoneal area available for exchange in children. Nephrol Dial Transplant 19(4):925\u2013932","journal-title":"Nephrol Dial Transplant"},{"key":"1716_CR14","first-page":"2","volume-title":"Some special problems in peritoneal dialysis","author":"M Usman","year":"2016","unstructured":"Usman M, Yeoungjee C, David WJ (2016) Peritoneal dialysis solutions. In: Robert E (ed) Some special problems in peritoneal dialysis. IntechOpen, Rijeka, p 2"},{"issue":"2","key":"1716_CR15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3747\/pdi.2012.00333","volume":"34","author":"TP de Moraes","year":"2014","unstructured":"de Moraes TP, Olandoski M, Caramori JC, Martin LC, Fernandes N, Divino-Filho JC et al (2014) Novel predictors of peritonitis-related outcomes in the BRAZPD cohort. Perit Dial Int 34(2):179\u2013187","journal-title":"Perit Dial Int"},{"issue":"1","key":"1716_CR16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3747\/pdi.2016.00018","volume":"37","author":"M Wiesholzer","year":"2017","unstructured":"Wiesholzer M, Winter A, Kussmann M, Zeitlinger M, Pichler P, Burgmann H et al (2017) Compatibility of meropenem with different commercial peritoneal dialysis solutions. Perit Dial Int 37(1):51\u201355","journal-title":"Perit Dial Int"},{"issue":"2","key":"1716_CR17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/0896860819887636","volume":"40","author":"TT Nguyen","year":"2020","unstructured":"Nguyen TT, Harmanjeet H, Wanandy T, Castelino RL, Sud K, Jose MD et al (2020) Pyridine levels in ceftazidime - peritoneal dialysis admixtures stored at body temperature. Perit Dial Int 40(2):171\u2013178","journal-title":"Perit Dial Int"},{"issue":"6","key":"1716_CR18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3747\/pdi.2015.00018","volume":"36","author":"G Deslandes","year":"2016","unstructured":"Deslandes G, Gr\u00e9goire M, Bouqui\u00e9 R, Le Marec A, Allard S, Dailly E et al (2016) Stability and compatibility of antibiotics in peritoneal dialysis solutions applied to automated peritoneal dialysis in the pediatric population. Perit Dial Int 36(6):676\u2013679","journal-title":"Perit Dial Int"},{"issue":"2","key":"1716_CR19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/03639049509048108","volume":"21","author":"M Mathew","year":"1995","unstructured":"Mathew M, Gupta VD (1995) Stability of vancomycin hydrochloride solutions at various PH values as determined by high-performance liquid chromatography. Drug Dev Ind Pharm 21(2):257\u2013264","journal-title":"Drug Dev Ind Pharm"},{"issue":"9","key":"1716_CR20","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/chromsci\/46.9.828","volume":"46","author":"M Enrique","year":"2008","unstructured":"Enrique M, Garc\u00eda-Montoya E, Mi\u00f1arro M, Orriols A, Tic\u00f3 JR, Su\u00f1\u00e9-Negre JM et al (2008) Application of an experimental design for the optimization and validation of a new HPLC method for the determination of vancomycin in an extemporaneous ophthalmic solution. J Chromatogr Sci 46(9):828\u2013834","journal-title":"J Chromatogr Sci"},{"issue":"6","key":"1716_CR21","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/AAC.44.6.1734-1736.2000","volume":"44","author":"RK Li","year":"2000","unstructured":"Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR (2000) In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 44(6):1734\u20131736","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1716_CR22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0732-8893(92)90053-V","volume":"15","author":"DW Denning","year":"1992","unstructured":"Denning DW, Hanson LH, Perlman AM, Stevens DA (1992) In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 15(1):21\u201334","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"1716_CR23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1186\/s12879-019-4237-3","volume":"19","author":"R Kariyawasam","year":"2019","unstructured":"Kariyawasam R, Challa P, Lau R, Boggild AK (2019) Susceptibility testing of Leishmania spp. against amphotericin B and fluconazole using the Sensititre\u2122 YeastOne\u2122 YO9 platform. BMC Infect Dis 19(1):593","journal-title":"BMC Infect Dis"},{"issue":"3","key":"1716_CR24","first-page":"157","volume":"8","author":"S Salama","year":"1997","unstructured":"Salama S, Rotstein C (1997) Reduction in the nephrotoxicity of amphotericin B when administered in 20% intralipid. Can J Infect Dis 8(3):157\u2013160","journal-title":"Can J Infect Dis"},{"issue":"1","key":"1716_CR25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/pharmaceutics12010029","volume":"12","author":"C Faustino","year":"2020","unstructured":"Faustino C, Pinheiro L (2020) Lipid systems for the delivery of amphotericin B in antifungal therapy. Pharmaceutics 12(1):29","journal-title":"Pharmaceutics"},{"issue":"2","key":"1716_CR26","first-page":"S298","volume":"7","author":"SY Lau","year":"2022","unstructured":"Lau SY, Bee BC, Wong HS, Tan CS (2022) POS-694 the role of intraperitoneal amphotericin b in peritoneal dialysis-related fungal peritonitis-experience from a Malaysian centre. Kidney Int Rep 7(2):S298\u2013S299","journal-title":"Kidney Int Rep"},{"issue":"4","key":"1716_CR27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/089686089001000408","volume":"10","author":"R Janknegt","year":"1990","unstructured":"Janknegt R, Paulissen A, Hooymans PM, Lohman JJ, Hermens WA (1990) Stability of amphotericin B in CAPD fluid. Perit Dial Int 10(4):287\u2013289","journal-title":"Perit Dial Int"},{"issue":"1","key":"1716_CR28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/089686080002000117","volume":"20","author":"HJ Manley","year":"2000","unstructured":"Manley HJ, Grabe DW, Norcross M, Cooperman TA, Stinchcomb AL, Hass M et al (2000) Stability of amphotericin B lipid complex (Abelcet) in peritoneal dialysis solutions. Perit Dial Int 20(1):87\u201390","journal-title":"Perit Dial Int"},{"issue":"3","key":"1716_CR29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","volume":"37","author":"LD Saravolatz","year":"2003","unstructured":"Saravolatz LD, Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH (2003) Amphotericin B: time for a new \u201cGold Standard.\u201d Clin Infect Dis 37(3):415\u2013425","journal-title":"Clin Infect Dis"},{"key":"1716_CR30","first-page":"2693","volume-title":"Chapter 148: anidulafungin","author":"JM Lestner","year":"2017","unstructured":"Lestner JM, Hope W (2017) Kucers\u2019 the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. In: Grayson ML, Crowe S, McCarthy JS, Cosgrove SE, Mouton JW, Hope W (eds) Chapter 148: anidulafungin, 7th edn. CRC Press, Cham, pp 2693\u20132706","edition":"7"},{"issue":"7","key":"1716_CR31","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3747\/pdi.2012.00326","volume":"34","author":"S Tobudic","year":"2014","unstructured":"Tobudic S, Donath O, Vychytil A, Forstner C, Poeppl W, Burgmann H (2014) Stability of anidulafungin in two standard peritoneal dialysis fluids. Perit Dial Int 34(7):798\u2013802","journal-title":"Perit Dial Int"},{"issue":"4","key":"1716_CR32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3747\/pdi.2010.00183","volume":"31","author":"SPL Peyro","year":"2011","unstructured":"Peyro SPL, Albessard F, Gaillard C, Debruyne D, Ryckelynck JP, Coquerel A et al (2011) Daptomycin compatibility in peritoneal dialysis solutions. Perit Dial Int 31(4):492\u2013495","journal-title":"Perit Dial Int"},{"issue":"16","key":"1716_CR33","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.3390\/polym13162725","volume":"13","author":"MM Abdelghafour","year":"2021","unstructured":"Abdelghafour MM, Orb\u00e1n \u00c1, De\u00e1k \u00c1, Lamch \u0141, Frank \u00c9, Nagy R et al (2021) The effect of molecular weight on the solubility properties of biocompatible poly(ethylene succinate) polyester. Polymers (Basel) 13(16):2725","journal-title":"Polymers (Basel)"},{"issue":"10","key":"1716_CR34","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1517\/17425255.2010.518143","volume":"6","author":"EL Kuti","year":"2010","unstructured":"Kuti EL, Kuti JL (2010) Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections. Expert Opin Drug Metab Toxicol 6(10):1287\u20131300","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1716_CR35","unstructured":"Ecalta 100 mg powder for concentrate for solution for infusion [prescribing information] Pfizer Limited, 2017. GlaxoSmithKline March."},{"issue":"2","key":"1716_CR36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2165\/00003495-198631020-00002","volume":"31","author":"RN Brogden","year":"1986","unstructured":"Brogden RN, Heel RC (1986) Aztreonam: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 31(2):96\u2013130","journal-title":"Drugs"},{"key":"1716_CR37","first-page":"644","volume-title":"Chapter 35: aztreonam and aztreonam-avibactam","author":"H Baba","year":"2017","unstructured":"Baba H (2017) Kucers\u2019 the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. In: Grayson ML, Crowe S, McCarthy JS, Cosgrove SE, Mouton JW, Hope W (eds) Chapter 35: aztreonam and aztreonam-avibactam. CRC Press, Cham, pp 644\u2013657"},{"issue":"Supplement_7","key":"1716_CR38","doi-asserted-by":"crossref","first-page":"S645","DOI":"10.1093\/clinids\/13.Supplement_7.S645","volume":"13","author":"M Dratwa","year":"1991","unstructured":"Dratwa M, Glupczynski Y, Lameire N, Matthys D, Verschraegen G, Vaneechoutte M et al (1991) Treatment of gram-negative peritonitis with aztreonam in patients undergoing continuous ambulatory peritoneal dialysis. Rev Infect Dis 13(Supplement_7):S645\u2013S647","journal-title":"Rev Infect Dis"},{"issue":"1","key":"1716_CR39","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41598-020-58391-y","volume":"10","author":"S Tobudic","year":"2020","unstructured":"Tobudic S, Prager I, Kussmann M, Oberm\u00fcller M, Ursli M, Zeitlinger M et al (2020) Compatibility of aztreonam in four commercial peritoneal dialysis fluids. Sci Rep 10(1):1788","journal-title":"Sci Rep"},{"issue":"3","key":"1716_CR40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003495-198325030-00001","volume":"25","author":"AA Carmine","year":"1983","unstructured":"Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS (1983) Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 25(3):223\u2013289","journal-title":"Drugs"},{"issue":"1","key":"1716_CR41","first-page":"21","volume":"6","author":"SK Nath","year":"1995","unstructured":"Nath SK, Foster GA, Mandell LA, Rotstein C (1995) Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin. Can J Infect Dis 6(1):21\u201327","journal-title":"Can J Infect Dis"},{"issue":"1","key":"1716_CR42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/089686080602600119","volume":"26","author":"JI Minguela","year":"2006","unstructured":"Minguela JI, de Pablos M, Castellanos T, Ruiz-de-Gauna R (2006) Peritonitis by Rhizobium radiobacter. Perit Dial Int 26(1):112","journal-title":"Perit Dial Int"},{"issue":"1","key":"1716_CR43","first-page":"147","volume":"47","author":"CM Paap","year":"1990","unstructured":"Paap CM, Nahata MC (1990) Stability of cefotaxime in two peritoneal dialysis solutions. Am J Hosp Pharm 47(1):147\u2013150","journal-title":"Am J Hosp Pharm"},{"issue":"3","key":"1716_CR44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0272-6386(83)80064-X","volume":"3","author":"DL Sewell","year":"1983","unstructured":"Sewell DL, Golper TA, Brown SD, Nelson E, Knower M, Kimbrough RC (1983) Stability of single and combination antimicrobial agents in various peritoneal dialysates in the presence of insulin and heparin. Am J Kidney Dis 3(3):209\u2013212","journal-title":"Am J Kidney Dis"},{"key":"1716_CR45","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v51i4.1965","author":"SE Walker","year":"1998","unstructured":"Walker SE, Varrin S, Yannicelli D, Law S (1998) Stability of meropenem in saline and dextrose solutions and compatibility with potassium chloride. Can J Hosp Pharm. https:\/\/doi.org\/10.4212\/cjhp.v51i4.1965","journal-title":"Can J Hosp Pharm"},{"issue":"8","key":"1716_CR46","first-page":"745","volume":"31","author":"EF Raffanti Jr","year":"1974","unstructured":"Raffanti EF Jr, King JC (1974) Effect of pH on the stability of sodium ampicillin solutions. Am J Hosp Pharm 31(8):745\u2013751","journal-title":"Am J Hosp Pharm"},{"issue":"3","key":"1716_CR47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/0148607190014003306","volume":"14","author":"DS Zaccardelli","year":"1990","unstructured":"Zaccardelli DS, Sanders Krcmarik C, Wolk R, Khalidi N (1990) Stability of imipenem and cilastatin sodium in total parenteral nutrient solution. J Parenter Enter Nutr 14(3):306\u2013309","journal-title":"J Parenter Enter Nutr"},{"issue":"11","key":"1716_CR48","first-page":"2803","volume":"43","author":"FP Bigley","year":"1986","unstructured":"Bigley FP, Forsyth RJ, Henley MW (1986) Compatibility of imipenem-cilastatin sodium with commonly used intravenous solutions. Am J Hosp Pharm 43(11):2803\u20132809","journal-title":"Am J Hosp Pharm"},{"issue":"SUPPL 3","key":"1716_CR49","first-page":"930","volume":"5","author":"S Farooqi","year":"2013","unstructured":"Farooqi S, Naqvi BS, Gauhar S (2013) Stability study of antibiotic (Cefotaxime) in peritoneal dialysis solution with validation of analyzing method. Int J Pharm Pharm Sci 5(SUPPL 3):930\u2013934","journal-title":"Int J Pharm Pharm Sci"},{"issue":"4","key":"1716_CR50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3747\/pdi.2016.00286","volume":"37","author":"FF Gir\u00f3n","year":"2017","unstructured":"Gir\u00f3n FF, Mart\u00edn JMS, G\u00f3mez ER, Mu\u00f1oz SC, Carmelo FG, G\u00f3mez IG et al (2017) Simultaneous Streptococcus canis and Pasteurella multocida peritonitis in a peritoneal dialysis patient. Perit Dial Int 37(4):483\u2013484","journal-title":"Perit Dial Int"},{"issue":"4","key":"1716_CR51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.15406\/unoaj.2020.08.00284","volume":"8","author":"MMC Mastrapasqua Sonia","year":"2020","unstructured":"Mastrapasqua Sonia MMC, Calfunao D (2020) Pasteurella multocida peritonitis in a CAPD patient case report and a review of literature. Urol Nephrol Open Access J 8(4):99\u2013100","journal-title":"Urol Nephrol Open Access J"},{"key":"1716_CR52","volume":"26","author":"PG Poliquin","year":"2015","unstructured":"Poliquin PG, Lagac\u00e9-Wiens P, Verrelli M, Allen DW, Embil JM (2015) Pasteurella Species peritoneal dialysis-associated peritonitis: household pets as a risk factor. Can J Infect Dis Med Microbiol 26:389467","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"7\u20138","key":"1716_CR53","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/106002809102500708","volume":"25","author":"MC Nahata","year":"1991","unstructured":"Nahata MC (1991) Stability of ceftriaxone sodium in peritoneal dialysis solutions. DICP 25(7\u20138):741\u2013742","journal-title":"DICP"},{"issue":"3","key":"1716_CR54","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/AAC.00860-06","volume":"51","author":"S Takeda","year":"2007","unstructured":"Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K (2007) In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 51(3):826\u2013830","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1716_CR55","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1128\/AAC.00834-09","volume":"54","author":"C Juan","year":"2010","unstructured":"Juan C, Zamorano L, P\u00e9rez JL, Ge Y, Oliver A (2010) Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 54(2):846\u2013851","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1716_CR56","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diagmicrobio.2011.02.004","volume":"70","author":"E Titelman","year":"2011","unstructured":"Titelman E, Karlsson IM, Ge Y, Giske CG (2011) In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 70(1):137\u2013141","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"1716_CR57","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0896860820902590","volume":"40","author":"H Harmanjeet","year":"2020","unstructured":"Harmanjeet H, Jani H, Zaidi STR, Wanandy T, Castelino RL, Sud K et al (2020) Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions. Perit Dial Int 40(5):470\u2013476","journal-title":"Perit Dial Int"},{"issue":"6","key":"1716_CR58","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/00006454-200206000-00010","volume":"21","author":"AL Frank","year":"2002","unstructured":"Frank AL, Marcinak JF, Mangat PD, Tjhio JT, Kelkar S, Schreckenberger PC et al (2002) Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 21(6):530","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"1716_CR59","first-page":"22","volume":"9","author":"M Smieja","year":"1998","unstructured":"Smieja M (1998) Current indications for the use of clindamycin: a critical review. Can J Infect Dis 9(1):22\u201328","journal-title":"Can J Infect Dis"},{"issue":"3","key":"1716_CR60","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/j.2055-2335.2012.tb00174.x","volume":"42","author":"MD Tran","year":"2012","unstructured":"Tran MD, Sharley N, Ward M (2012) Stability of amoxycillin, clindamycin and meropenem in peritoneal dialysis solution. J Pharm Pract Res 42(3):218\u2013222","journal-title":"J Pharm Pract Res"},{"issue":"2","key":"1716_CR61","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/089686088800800209","volume":"8","author":"WA Kehoe","year":"1988","unstructured":"Kehoe WA, Weber JN, Fries DS (1988) The stability and compatibility of clindamycin phosphate and gentamicin sulfate alone and in combination in peritoneal dialysis solution. Perit Dial Int 8(2):153\u2013154","journal-title":"Perit Dial Int"},{"key":"1716_CR62","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/infdis\/128.Supplement_3.S543","volume":"128","author":"SJ Seligman","year":"1973","unstructured":"Seligman SJ (1973) In vitro susceptibility of methicillin-resistant Staphylococcus aureus to sulfamethoxazole and trimethoprim. J Infect Dis 128:543\u2013544","journal-title":"J Infect Dis"},{"issue":"7","key":"1716_CR63","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0732-8893(90)90037-V","volume":"15","author":"KE Aldridge","year":"1992","unstructured":"Aldridge KE, Gelfand MS, Schiro DD, Barg NL (1992) The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital. An in vitro look at alternative antimicrobial agents. Diagn Microbiol Infect Dis 15(7):601\u2013608","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"1716_CR64","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1128\/AAC.27.4.449","volume":"27","author":"A Iravani","year":"1985","unstructured":"Iravani A, Welty GS, Newton BR, Richard GA (1985) Effects of changes in pH, medium, and inoculum size on the in vitro activity of amifloxacin against urinary isolates of Staphylococcus saprophyticus and Escherichia coli. Antimicrob Agents Chemother 27(4):449\u2013451","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1716_CR65","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/AAC.31.2.144","volume":"31","author":"C Jones","year":"1987","unstructured":"Jones C, Stevens DL, Ojo O (1987) Effect of minimal amounts of thymidine on activity of trimethoprim-sulfamethoxazole against Staphylococcus epidermidis. Antimicrob Agents Chemother 31(2):144\u2013147","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1716_CR66","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/089686089001000207","volume":"10","author":"SE Holmes","year":"1990","unstructured":"Holmes SE, Aldous S (1990) Stability of cotrimoxazole in peritoneal dialysis fluid. Perit Dial Int 10(2):157\u2013160","journal-title":"Perit Dial Int"},{"key":"1716_CR67","unstructured":"Bactrim 400\/80 (Sulfamethoxazole 400mg\/5mL and trimethoprim 80mg\/5mL concentrate for solution for infusion)[Prescribing information], Pfizer Limited, 2022."},{"issue":"3","key":"1716_CR68","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/dkg337","volume":"52","author":"PK Dandekar","year":"2003","unstructured":"Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP (2003) Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 52(3):405\u2013411","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"1716_CR69","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1128\/AAC.00678-06","volume":"50","author":"M Wootton","year":"2006","unstructured":"Wootton M, MacGowan AP, Walsh TR (2006) Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob Agents Chemother 50(12):4195\u20134197","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1716_CR70","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3747\/pdi.2012.00120","volume":"33","author":"MA Parra","year":"2013","unstructured":"Parra MA, Campanero MA, S\u00e1daba B, Irigoyen A, Garc\u00eda-L\u00f3pez L, Fernandez-Reyes MJ et al (2013) Effect of glucose concentration on the stability of daptomycin in peritoneal solutions. Perit Dial Int 33(4):458\u2013461","journal-title":"Perit Dial Int"},{"issue":"1","key":"1716_CR71","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/ejhpharm-2015-000651","volume":"23","author":"S Ramdas","year":"2016","unstructured":"Ramdas S, Yousaf F, Shastri MD, Wanandy T, Zaidi STR, Khandagale M et al (2016) Stability of daptomycin in peritoneal dialysis solutions packaged in dual-compartment infusion bags. Eur J Hosp Pharm 23(1):57\u201360","journal-title":"Eur J Hosp Pharm"},{"key":"1716_CR72","unstructured":"Cubicin (daptomycin for injection), for Intravenous Use [prescribing information], Merck Sharp & Dohme LLC 2022."},{"key":"1716_CR73","unstructured":"Cubicin RF (daptomycin for injection), for intravenous use [prescribing information], Merck Sharp & Dohme LLC 2017."},{"issue":"3","key":"1716_CR74","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0025-6196(12)60219-5","volume":"60","author":"JA Washington II","year":"1985","unstructured":"Washington JA II, Wilson WR (1985) Erythromycin: a microbial and clinical perspective after 30 years of clinical use (first of two parts). Mayo Clin Proc 60(3):189\u2013203","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1716_CR75","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/089686089401400116","volume":"14","author":"MP Kane","year":"1994","unstructured":"Kane MP, Bailie GR, Moon DG, Siu I, Eisele G (1994) Stability of erythromycin lactobionate in peritoneal dialysate solutions. Perit Dial Int 14(1):79\u201381","journal-title":"Perit Dial Int"},{"issue":"1","key":"1716_CR76","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1749-6632.1974.tb43277.x","volume":"235","author":"FM Kahan","year":"1974","unstructured":"Kahan FM, Kahan JS, Cassidy PJ, Kropp H (1974) The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 235(1):364\u2013386","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"1716_CR77","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","volume":"15","author":"AS Michalopoulos","year":"2011","unstructured":"Michalopoulos AS, Livaditis IG, Gougoutas V (2011) The revival of fosfomycin. Int J Infect Dis 15(11):e732\u2013e739","journal-title":"Int J Infect Dis"},{"issue":"11","key":"1716_CR78","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1007\/s10096-017-3051-3","volume":"36","author":"M Kussmann","year":"2017","unstructured":"Kussmann M, Baumann A, Hauer S, Pichler P, Zeitlinger M, Wiesholzer M et al (2017) Compatibility of fosfomycin with different commercial peritoneal dialysis solutions. Eur J Clin Microbiol Infect Dis 36(11):2237\u20132242","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"1716_CR79","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1128\/AAC.00126-12","volume":"56","author":"S Tobudic","year":"2012","unstructured":"Tobudic S, Matzneller P, Stoiser B, Wenisch JM, Zeitlinger M, Vychytil A et al (2012) Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis. Antimicrob Agents Chemother 56(7):3992\u20133995","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1716_CR80","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0149-2918(01)80043-6","volume":"23","author":"HB Fung","year":"2001","unstructured":"Fung HB, Kirschenbaum HL, Ojofeitimi BO (2001) Linezolid: an oxazolidinone antimicrobial agent. Clin Ther 23(3):356\u2013391","journal-title":"Clin Ther"},{"issue":"3","key":"1716_CR81","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/089686080202200321","volume":"22","author":"HJ Manley","year":"2002","unstructured":"Manley HJ, McClaran ML, Bedenbaugh A, Peloquin CA (2002) Linezolid stability in peritoneal dialysis solutions. Perit Dial Int 22(3):419\u2013422","journal-title":"Perit Dial Int"},{"issue":"19","key":"1716_CR82","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2146\/ajhp170318","volume":"75","author":"W Poeppl","year":"2018","unstructured":"Poeppl W, Rainer-Harbach E, Kussmann M, Pichler P, Zeitlinger M, Wiesholzer M et al (2018) Compatibility of linezolid with commercial peritoneal dialysis solutions. Am J Health Syst Pharm 75(19):1467\u20131477","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"1716_CR83","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0732-8893(03)00115-9","volume":"47","author":"KVI Rolston","year":"2003","unstructured":"Rolston KVI, Frisbee-Hume S, LeBlanc B, Streeter H, Hsi HD (2003) In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients. Diagn Microbiol Infect Dis 47(2):441\u2013449","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"1716_CR84","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00003495-200059010-00010","volume":"59","author":"JA Balfour","year":"2000","unstructured":"Balfour JA, Lamb HM (2000) Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 59(1):115\u2013139","journal-title":"Drugs"},{"issue":"3","key":"1716_CR85","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1592\/phco.20.4.245.34880","volume":"20","author":"CH Nightingale","year":"2000","unstructured":"Nightingale CH (2000) Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy 20(3):245\u2013256","journal-title":"Pharmacotherapy"},{"issue":"2","key":"1716_CR86","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jac\/46.2.334","volume":"46","author":"JL Bellido","year":"2000","unstructured":"Bellido JL, Hern\u00e1ndez FJ, Zufiaurre MN, Garc\u00eda-Rodr\u00edguez JA (2000) In vitro activity of newer fluoroquinolones against Stenotrophomonas maltophilia. J Antimicrob Chemother 46(2):334\u2013335","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1716_CR87","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/jac\/45.3.363","volume":"45","author":"K Weiss","year":"2000","unstructured":"Weiss K, Restieri C, De Carolis E, Laverdi\u00e8re M, Guay H (2000) Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 45(3):363\u2013365","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1716_CR88","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2710.2006.00758.x","volume":"31","author":"E Fern\u00e1ndez-Var\u00f3n","year":"2006","unstructured":"Fern\u00e1ndez-Var\u00f3n E, Mar\u00edn P, Espuny A, Villamayor L, Escudero E, C\u00e1rceles C (2006) Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1.36% and Dianeal PD1 3.86%). J Clin Pharm Ther 31(6):641\u2013643","journal-title":"J Clin Pharm Ther"},{"key":"1716_CR89","unstructured":"Inman E, Kirsch, LE (1990) Inventor: an improved diluent formulation for daptomycin. European Patent Office, patent number 0386951 A2 USA. Date of publication of application: 12 September 1990. Accessed 13 July 2022"},{"issue":"11","key":"1716_CR90","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1177\/106002808902301101","volume":"23","author":"MA Smythe","year":"1989","unstructured":"Smythe MA, Rybak MJ (1989) Ofloxacin: a review. DICP 23(11):839\u2013846","journal-title":"DICP"},{"issue":"2","key":"1716_CR91","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/089686080902902S32","volume":"29","author":"T Akpolat","year":"2009","unstructured":"Akpolat T (2009) Tuberculous peritonitis. Perit Dial Int 29(2):166\u2013169","journal-title":"Perit Dial Int"},{"issue":"6","key":"1716_CR92","first-page":"277","volume":"28","author":"MK Chan","year":"1987","unstructured":"Chan MK, Chau PY, Chan WW (1987) Ofloxacin pharmacokinetics in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 28(6):277\u2013280","journal-title":"Clin Nephrol"},{"issue":"1","key":"1716_CR93","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/089686089501500115","volume":"15","author":"C Battista","year":"1995","unstructured":"Battista C, Kane MP, Moon DG, Bailie GR (1995) Stability of ofloxacin in peritoneal dialysis solutions. Perit Dial Int 15(1):72\u201374","journal-title":"Perit Dial Int"},{"issue":"Suppl A","key":"1716_CR94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/21.suppl_A.1","volume":"21","author":"D Greenwood","year":"1988","unstructured":"Greenwood D (1988) Microbiological properties of teicoplanin. J Antimicrob Chemother 21(Suppl A):1\u201313","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1716_CR95","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12866-022-02753-1","volume":"23","author":"GV Zacharopoulos","year":"2023","unstructured":"Zacharopoulos GV, Manios GA, Papadakis M, Koumaki D, Maraki S, Kassotakis D et al (2023) Comparative activities of ampicillin and teicoplanin against Enterococcus faecalis isolates. BMC Microbiol 23(1):5","journal-title":"BMC Microbiol"},{"issue":"1","key":"1716_CR96","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1186\/s12879-021-06280-8","volume":"21","author":"Y Kang","year":"2021","unstructured":"Kang Y, Chen Y, Zhang Z, Shen H, Zhou W, Wu C (2021) A case of peritoneal dialysis-associated peritonitis caused by Rhodococcus kroppenstedtii. BMC Infect Dis 21(1):565","journal-title":"BMC Infect Dis"},{"issue":"22","key":"1716_CR97","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/ajhp\/53.22.2731","volume":"53","author":"M Manduru","year":"1996","unstructured":"Manduru M, Fariello A, White RL, Fox JL, Bosso JA (1996) Stability of ceftazidime sodium and teicoplanin sodium in a peritoneal dialysis solution. Am J Health Syst Pharm 53(22):2731\u20132734","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"1716_CR98","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1179\/joc.2007.19.2.232","volume":"19","author":"BA Cunha","year":"2007","unstructured":"Cunha BA (2007) Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant gram-negative bacteremias. J Chemother 19(2):232\u2013233","journal-title":"J Chemother"},{"issue":"6","key":"1716_CR99","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1179\/joc.2007.19.6.753","volume":"19","author":"BA Cunha","year":"2007","unstructured":"Cunha BA, McDermott B, Nausheen S (2007) Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection. J Chemother 19(6):753\u2013754","journal-title":"J Chemother"},{"issue":"3","key":"1716_CR100","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/jac\/dkl514","volume":"59","author":"N Woodford","year":"2007","unstructured":"Woodford N, Hill RL, Livermore DM (2007) In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp. J Antimicrob Chemother 59(3):582\u2013583","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"1716_CR101","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1128\/AAC.40.9.2226","volume":"40","author":"J Bergeron","year":"1996","unstructured":"Bergeron J, Ammirati M, Danley D, James L, Norcia M, Retsema J et al (1996) Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 40(9):2226\u20132228","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1716_CR102","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003495-200464010-00005","volume":"64","author":"GG Zhanel","year":"2004","unstructured":"Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J et al (2004) The glycylcyclines: a comparative review with the tetracyclines. Drugs 64(1):63\u201388","journal-title":"Drugs"},{"issue":"4","key":"1716_CR103","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3747\/pdi.2015.00170","volume":"36","author":"R Robiyanto","year":"2016","unstructured":"Robiyanto R, Zaidi ST, Shastri MD, Castelino RL, Wanandy ST, Jose MD et al (2016) Stability of tigecycline in different types of peritoneal dialysis solutions. Perit Dial Int 36(4):410\u2013414","journal-title":"Perit Dial Int"},{"issue":"3","key":"1716_CR104","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2165\/00003495-197612030-00002","volume":"12","author":"RN Brogden","year":"1976","unstructured":"Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS (1976) Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs 12(3):166\u2013200","journal-title":"Drugs"},{"issue":"6","key":"1716_CR105","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/089686080402400619","volume":"24","author":"M Voges","year":"2004","unstructured":"Voges M, Faict D, Lechien G, Taminne M (2004) Stability of drug additives in peritoneal dialysis solutions in a new container. Perit Dial Int 24(6):590\u2013595","journal-title":"Perit Dial Int"},{"issue":"1","key":"1716_CR106","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/089686080902900108","volume":"29","author":"KE Pallotta","year":"2009","unstructured":"Pallotta KE, Elwell RJ, Nornoo AO, Manley HJ (2009) Stability of tobramycin and ceftazidime in icodextrin peritoneal dialysis solution. Perit Dial Int 29(1):52\u201357","journal-title":"Perit Dial Int"},{"issue":"5","key":"1716_CR107","first-page":"1139","volume":"49","author":"NA Mason","year":"1992","unstructured":"Mason NA, Johnson GE, O\u2019Brien MA (1992) Stability of ceftazidime and tobramycin sulfate in peritoneal dialysis solution. Am J Hosp Pharm 49(5):1139\u20131142","journal-title":"Am J Hosp Pharm"},{"issue":"3","key":"1716_CR108","doi-asserted-by":"crossref","first-page":"217","DOI":"10.59566\/IJBS.2006.2217","volume":"2","author":"IA Darwish","year":"2006","unstructured":"Darwish IA (2006) Immunoassay methods and their applications in pharmaceutical analysis: basic methodology and recent advances. Int J Biomed Sci 2(3):217\u2013235","journal-title":"Int J Biomed Sci"},{"key":"1716_CR109","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/chromsci\/12.5.269","volume":"12","author":"ML Bastos","year":"1974","unstructured":"Bastos ML, Hoffman DB (1974) Comparison of methods for detection of amphetamines, cocaine and metabolites. J Chromatogr Sci 12:269\u2013280","journal-title":"J Chromatogr Sci"},{"issue":"1","key":"1716_CR110","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1186\/s12882-020-02113-z","volume":"21","author":"F Fontana","year":"2020","unstructured":"Fontana F, Torelli C, Giovanella S, Ligabue G, Alfano G, Gerritsen K et al (2020) Influence of dialysate temperature on creatinine peritoneal clearance in peritoneal dialysis patients: a randomized trial. BMC Nephrol 21(1):448","journal-title":"BMC Nephrol"},{"issue":"3","key":"1716_CR111","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/089686080302300301","volume":"23","author":"AGA Welten","year":"2003","unstructured":"Welten AGA, Schalkwijk CG, Ter Wee PM, Meijer S, Van Den Born J, Beelen RJH (2003) Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int 23(3):213\u2013221","journal-title":"Perit Dial Int"},{"issue":"1","key":"1716_CR112","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/1076029607304722","volume":"15","author":"J Gozdzikiewicz","year":"2009","unstructured":"Gozdzikiewicz J, Borawski J, Mysliwiec M (2009) Pleiotropic effects of heparin and heparinoids in peritoneal dialysis. Clin Appl Thromb Hemost 15(1):92\u201397","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"1716_CR113","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3747\/pdi.2017.00115","volume":"38","author":"S Kandel","year":"2018","unstructured":"Kandel S, Zaidi STR, Wanandy ST, Ming LC, Castelino RL, Sud K et al (2018) Stability of ceftazidime and heparin in four different types of peritoneal dialysis solutions. Perit Dial Int 38(1):49\u201356","journal-title":"Perit Dial Int"},{"issue":"5","key":"1716_CR114","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/106002809402800503","volume":"28","author":"LM Vaughan","year":"1994","unstructured":"Vaughan LM, Poon CY (1994) Stability of ceftazidime and vancomycin alone and in combination in heparinized and nonheparinized peritoneal dialysis solution. Ann Pharmacother 28(5):572\u2013576","journal-title":"Ann Pharmacother"},{"issue":"12","key":"1716_CR115","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/jcp.33.12.1206","volume":"33","author":"KT Goodall","year":"1980","unstructured":"Goodall KT, Chooi CC, Gallus AS (1980) Heparin stability: effects of diluent, heparin activity, container, and pH. J Clin Pathol 33(12):1206\u20131211","journal-title":"J Clin Pathol"},{"issue":"5","key":"1716_CR116","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/jps.21556","volume":"98","author":"RP Patel","year":"2009","unstructured":"Patel RP, Narkowicz C, Jacobson GA (2009) Investigation of the effect of heating on the chemistry and antifactor Xa activity of enoxaparin. J Pharm Sci 98(5):1700\u20131711","journal-title":"J Pharm Sci"},{"issue":"3","key":"1716_CR117","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/jps.21483","volume":"98","author":"RP Patel","year":"2009","unstructured":"Patel RP, Narkowicz C, Jacobson GA (2009) Investigation of freezing- and thawing-induced biological, chemical, and physical changes to enoxaparin solution. J Pharm Sci 98(3):1118\u20131128","journal-title":"J Pharm Sci"},{"issue":"4","key":"1716_CR118","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1469-0691.2001.00233.x","volume":"7","author":"JA Capdevila","year":"2001","unstructured":"Capdevila JA, Gavald\u00e0 J, Fortea J, L\u00f3pez P, Martin MT, Gomis X et al (2001) Lack of antimicrobial activity of sodium heparin for treating experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock technique. Clin Microbiol Infect 7(4):206\u2013212","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"1716_CR119","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/089686080902900101","volume":"29","author":"F De Vin","year":"2009","unstructured":"De Vin F, Rutherford P, Faict D (2009) Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. Perit Dial Int 29(1):5\u201315","journal-title":"Perit Dial Int"},{"issue":"7","key":"1716_CR120","first-page":"1604","volume":"47","author":"JM Drake","year":"1990","unstructured":"Drake JM, Myre SA, Staneck JL, Draeger RW (1990) Antimicrobial activity of vancomycin, gentamicin, and tobramycin in peritoneal dialysis solution. Am J Hosp Pharm 47(7):1604\u20131606","journal-title":"Am J Hosp Pharm"},{"issue":"3","key":"1716_CR121","first-page":"212","volume":"63","author":"SE Walker","year":"2010","unstructured":"Walker SE, Iazzetta J, Law S, Biniecki K (2010) Stability of commonly used antibiotic solutions in an elastomeric infusion device. Can J Hosp Pharm 63(3):212\u2013224","journal-title":"Can J Hosp Pharm"},{"issue":"2","key":"1716_CR122","first-page":"369","volume":"47","author":"HJ Martens","year":"1990","unstructured":"Martens HJ, De Goede PN, Van Loenen AC (1990) Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am J Hosp Pharm 47(2):369\u2013373","journal-title":"Am J Hosp Pharm"},{"issue":"3","key":"1716_CR123","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1163\/156856295X00247","volume":"7","author":"L Tchiakp\u00e9","year":"1996","unstructured":"Tchiakp\u00e9 L, Airaudo CB, Ould MA, Gayte-Sorbier A, Verdier M, Guerri J (1996) Stedim 6\u00ae and Clearflex\u00ae, two new multilayer materials for infusion containers. Comparative study of their compatibility with five drugs versus glass flasks and polyvinyl chloride bags. J Biomater Sci Polym Ed 7(3):199\u2013206","journal-title":"J Biomater Sci Polym Ed"},{"issue":"6","key":"1716_CR124","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/089686080502500613","volume":"25","author":"C Hamada","year":"2005","unstructured":"Hamada C, Hayashi K, Shou I, Inaba M, Ro Y, Io H et al (2005) Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients. Perit Dial Int 25(6):570\u2013575","journal-title":"Perit Dial Int"},{"issue":"9","key":"1716_CR125","first-page":"1308","volume":"38","author":"EA Kowaluk","year":"1981","unstructured":"Kowaluk EA, Roberts MS, Blackburn HD, Polack AE (1981) Interactions between drugs and polyvinyl chloride infusion bags. Am J Hosp Pharm 38(9):1308\u20131314","journal-title":"Am J Hosp Pharm"},{"issue":"4","key":"1716_CR126","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/embor.2012.36","volume":"13","author":"DL Vaux","year":"2012","unstructured":"Vaux DL, Fidler F, Cumming G (2012) Replicates and repeats-what is the difference and is it significant? A brief discussion of statistics and experimental design. EMBO Rep 13(4):291\u2013296","journal-title":"EMBO Rep"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01716-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-023-01716-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01716-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:52:36Z","timestamp":1777564356000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/36\/7\/1841\/8304180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":126,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["1716"],"URL":"https:\/\/doi.org\/10.1007\/s40620-023-01716-7","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"23 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kamal Sud has received speaker\u2019s honoraria from Baxter Healthcare and is also on the medical advisory board of Fresenius Medical Care for Australia and New Zealand. Other authors declared no conflict of interest regarding the research, authorship, and publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}